ValuEngine cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a report published on Thursday morning.

LMAT has been the subject of a number of other reports. Roth Capital began coverage on shares of LeMaitre Vascular in a report on Friday, June 8th. They issued a buy rating and a $38.00 price objective for the company. BidaskClub lowered shares of LeMaitre Vascular from a strong-buy rating to a buy rating in a report on Friday, June 8th. Stifel Nicolaus lowered shares of LeMaitre Vascular from a buy rating to a hold rating and lowered their price objective for the stock from $40.00 to $34.00 in a report on Thursday, April 26th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and set a $40.00 price objective for the company in a report on Wednesday, February 28th. Finally, Canaccord Genuity restated a hold rating and issued a $33.00 price objective on shares of LeMaitre Vascular in a report on Friday, February 23rd. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $36.50.

Shares of LMAT opened at $35.18 on Thursday. The company has a market capitalization of $676.71 million, a PE ratio of 39.82, a price-to-earnings-growth ratio of 2.15 and a beta of 0.57. LeMaitre Vascular has a fifty-two week low of $26.37 and a fifty-two week high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, April 25th. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.02). The business had revenue of $25.99 million during the quarter, compared to the consensus estimate of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.16 earnings per share. research analysts predict that LeMaitre Vascular will post 1.09 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, June 7th. Investors of record on Tuesday, May 22nd were issued a dividend of $0.07 per share. The ex-dividend date was Monday, May 21st. This represents a $0.28 dividend on an annualized basis and a yield of 0.80%. LeMaitre Vascular’s dividend payout ratio is currently 32.56%.

In related news, insider Trent G. Kamke sold 12,368 shares of the company’s stock in a transaction on Friday, May 25th. The shares were sold at an average price of $32.83, for a total transaction of $406,041.44. Following the completion of the sale, the insider now directly owns 20,424 shares in the company, valued at approximately $670,519.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman George W. Lemaitre sold 15,000 shares of the company’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $37.07, for a total transaction of $556,050.00. Following the sale, the chairman now owns 3,073,802 shares of the company’s stock, valued at $113,945,840.14. The disclosure for this sale can be found here. Insiders have sold a total of 120,598 shares of company stock valued at $4,144,663 over the last quarter. 20.30% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. raised its holdings in LeMaitre Vascular by 73.8% during the 1st quarter. Victory Capital Management Inc. now owns 5,076 shares of the medical instruments supplier’s stock valued at $184,000 after buying an additional 2,156 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in LeMaitre Vascular during the 1st quarter valued at $215,000. Citadel Advisors LLC bought a new stake in LeMaitre Vascular during the 1st quarter valued at $241,000. Advisor Group Inc. raised its holdings in LeMaitre Vascular by 28.3% during the 4th quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock valued at $223,000 after buying an additional 1,550 shares during the last quarter. Finally, MetLife Investment Advisors LLC bought a new position in LeMaitre Vascular in the 4th quarter worth $244,000. Institutional investors own 72.87% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.